Alzheimer's Disease and AD-related dementias (ADRDs) (Frontotemporal Dementia, Lewy Body Dementia, etc.) are devastating neurodegenerative disorders whose onset is correlated with age. Due to the increase of human life span in the 20th century, Alzheimer's and ADRDs have become a major medical, societal and economic issue of today. In spite of decades of research and clinical efforts, cures have been elusive, and Alzheimer's has become the 6th cause of death in the USA. New hypotheses, mechanisms and drug targets for Alzheimer's and ADRDs are urgently needed. One promising direction is inflammation: aging and many age-related diseases are thought to be causally linked with a chronic inflammatory state known as inflammaging. Alzheimer's is no exception, and neuroinflammation establishes an environment in the brain that is hostile for the function and survival of neurons. While it is not yet clear if neuroinflammation is a cause of Alzheimer's, it is increasingly believed that alleviating neuroinflammatory processes might slow down Alzheimer's Disease progression. Cell senescence is an irreversible arrest of proliferation due to a variety of stresses. It is characterized by the secretion of proinflammatory molecules, the senescence associated secretory phenotype (SASP). The paracrine effect of the SASP on surrounding cells is a key mechanism by which senescent cells promote age-associated diseases. Essentially all brain cells, including astrocytes, microglia and neurons, can become senescent. The frequency of senescent cells increases in Alzheimer's and ADRDs. Removing senescent cells in mouse models of Alzheimer's reduces neuroinflammation, alleviates pathology and improves cognitive function. We discovered a novel mechanism which maintains and propagates cell senescence, and thus inflammation. Retrotransposable elements (RTEs), known as Long Interspersed Nuclear Elements (LINE-1, or L1) are activated in senescent cells and induce a type-I interferon (IFN-I) response, which in turn drives the SASP. The IFN-I response is triggered by innate immune system DNA sensors that detect cytoplasmic L1 cDNAs, whose synthesis can be blocked by nucleoside reverse transcriptase inhibitor (NRTI) drugs. NRTIs were developed to treat HIV, and several well- tolerated drugs potently inhibit the L1 reverse transcriptase (RT). On the basis of this evidence we hypothesize that L1 activation is an important component of Alzheimer's neuroinflammation and that L1 is a relevant drug target for the treatment of Alzheimer's and ADRDs. We propose the following Specific Aims: 1) To investigate the genesis of L1 cDNAs in the cytoplasm of senescent cells. This will define new targets and target engagement assays for NRTI treatment of neuroinflammation in Alzheimer's. 2) To apply NRTI therapy to mouse models of Alzheimer's and other neurodegenerative diseases. Due to their good blood-brain barrier penetration NRTI drugs hold great promise for the treatment of Alzheimer's and ADRDs.
Aim 3 : To assess the efficacy of available NRTIs to inhibit L1, as well as to develop new drugs against L1-encoded enzymes. In aggregate, this research will shed new light on the mechanisms of neuroinflammation and advance new treatments for Alzheimer's and ADRDs.

Public Health Relevance

Retrotransposable elements are viral-like entities that exist within the DNA of our cells. During aging these molecular parasites are prone to activation, with deleterious effects on their host cells, such as inflammation. Our goal is to develop drugs to block these elements, which we expect will alleviate age-associated diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
2R01AG016694-21
Application #
9886815
Study Section
Cellular Mechanisms in Aging and Development Study Section (CMAD)
Program Officer
Guo, Max
Project Start
1999-04-01
Project End
2025-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Brown University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
001785542
City
Providence
State
RI
Country
United States
Zip Code
02912
Waaijer, Mariƫtte E C; Gunn, David A; van Heemst, Diana et al. (2018) Do senescence markers correlate in vitro and in situ within individual human donors? Aging (Albany NY) 10:278-289
Ito, Takahiro; Teo, Yee Voan; Evans, Shane A et al. (2018) Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways. Cell Rep 22:3480-3492
Tatar, Marc; Sedivy, John M (2016) Mitochondria: Masters of Epigenetics. Cell 165:1052-1054
Hofmann, Jeffrey W; Zhao, Xiaoai; De Cecco, Marco et al. (2015) Reduced expression of MYC increases longevity and enhances healthspan. Cell 160:477-88
Waaijer, Mariƫtte E C; Parish, William E; Strongitharm, Barbara H et al. (2012) The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell 11:722-5
Alves, Hugo; Munoz-Najar, Ursula; De Wit, Jan et al. (2010) A link between the accumulation of DNA damage and loss of multi-potency of human mesenchymal stromal cells. J Cell Mol Med 14:2729-38
Liu, Yen-Chun; Li, Feng; Handler, Jesse et al. (2008) Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One 3:e2722
Sedivy, John M; Banumathy, Gowrishankar; Adams, Peter D (2008) Aging by epigenetics--a consequence of chromatin damage? Exp Cell Res 314:1909-17
Jeyapalan, Jessie C; Sedivy, John M (2008) Cellular senescence and organismal aging. Mech Ageing Dev 129:467-74
Schorl, Christoph; Sedivy, John M (2007) Analysis of cell cycle phases and progression in cultured mammalian cells. Methods 41:143-50

Showing the most recent 10 out of 26 publications